scholarly journals Former smoking and early and long-term graft outcome in renal transplant recipients: a retrospective cohort study

2017 ◽  
Vol 30 (2) ◽  
pp. 187-195 ◽  
Author(s):  
Steven Van Laecke ◽  
Evi Vanessa Nagler ◽  
Patrick Peeters ◽  
Francis Verbeke ◽  
Wim Van Biesen
Keyword(s):  
Cohort Study ◽  
Renal Transplant ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Graft Outcome

scholarly journals Effect of long-term steroid withdrawal in renal transplant recipients: a retrospective cohort study

2010 ◽  
Vol 3 (suppl 2) ◽  
pp. ii32-ii36 ◽  
Author(s):  
M. Gonzalez-Molina ◽  
M. A. Gentil ◽  
D. Burgos ◽  
M. Cabello ◽  
C. Cobelo ◽  
...  
Keyword(s):  
Cohort Study ◽  
Renal Transplant ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Renal Transplant Recipients ◽  
Steroid Withdrawal ◽  
Transplant Recipients

scholarly journals A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients

PLoS ONE ◽  
2017 ◽  
Vol 12 (6) ◽  
pp. e0178801 ◽  
Author(s):  
Lilli Gard ◽  
Willem van Doesum ◽  
Hubert G. M. Niesters ◽  
Willem J. van Son ◽  
Arjan Diepstra ◽  
...  
Keyword(s):  
Cohort Study ◽  
Renal Transplant ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Delicate Balance ◽  
Bk Polyomavirus

scholarly journals Novel Oral Anticoagulants in Renal Transplant Recipients: A Retrospective Cohort Study

PRILOZI ◽  
2020 ◽  
Vol 41 (2) ◽  
pp. 49-55
Author(s):  
Nikolina Basic-Jukic ◽  
Vesna Furic-Cunko ◽  
Ivana Juric
Keyword(s):  
Cohort Study ◽  
Renal Transplant ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Hematological Parameters ◽  
Graft Function ◽  
Bleeding Event ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Anticoagulant Drugs

AbstractAim: Data on the use of novel anticoagulant drugs (NOACc) in renal transplant recipients is scarce. The aim of our study was to investigate the safety and efficacy of NOACs in renal transplant recipients.Materials and Methods: In a single-centre retrospective cohort study we assessed adverse reactions, thromboembolic events, and interactions of calcineurin inhibitors in patients treated with NOACs.Results: Twenty-three renal transplant recipients were treated with NOACs (70% male), mean age of 65.8 ± 1.8 years. Fourteen (61%) patients were treated with rivaroxaban, apixaban was given to 8 (35%) of our patients, and dabigatran to one patient (4%). The main indications for NOAC therapy was atrial fibrillation in 61% and deep venous thrombosis in 23% of patients. Bleeding occurred in 2 patients (1 treated with rivaroxaban and 1 with dabigatran). None of our patients developed thrombosis while treated with NOAC. During the median follow-up of 24 months graft function, as well as hematological parameters, remained stable in patients that were treated with rivaroxaban and apixaban, while dabigatran was ceased after a month of therapy due to a bleeding event.Conclusion: Our results show that both rivaroxaban and apixaban are safe and efficient oral anticoagulant drugs in renal transplant patients. Additional studies are needed to prove these results.

scholarly journals Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Vatsa Dave ◽  
Kevan R. Polkinghorne ◽  
Khai Gene Leong ◽  
John Kanellis ◽  
William R. Mulley
Keyword(s):  
Renal Function ◽  
Cohort Study ◽  
Renal Transplant ◽  
Graft Function ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Post Transplantation ◽  
Post Transplant ◽  
Increased Risk

Abstract The evidence supporting an initial mycophenolate mofetil (MMF) dose of 2 g daily in tacrolimus-treated renal transplant recipients is limited. In a non-contemporaneous single-centre cohort study we compared the incidence of leukopaenia, rejection and graft dysfunction in patients initiated on MMF 1.5 g and 2 g daily. Baseline characteristics and tacrolimus trough levels were similar by MMF group. MMF doses became equivalent between groups by 12-months post-transplant, driven by dose reductions in the 2 g group. Leukopaenia occurred in 42.4% of patients by 12-months post-transplant. MMF 2 g was associated with a 1.80-fold increased risk of leukopaenia compared to 1.5 g. Rejection occurred in 44.8% of patients by 12-months post-transplantation. MMF 2 g was associated with half the risk of rejection relative to MMF 1.5 g. Over the first 7-years post-transplantation there was no difference in renal function between groups. Additionally, the development of leukopaenia or rejection did not result in reduced renal function at 7-years post-transplant. Leukopaenia was not associated with an increased incidence of serious infections or rejection. This study demonstrates the initial MMF dose has implications for the incidence of leukopaenia and rejection. Since neither dose produced superior long-term graft function, clinical equipoise remains regarding the optimal initial mycophenolate dose in tacrolimus-treated renal transplant recipients.

scholarly journals 1674. Epidemiology of Urinary Tract Infections in the Renal Transplant Population in a Large Urban Midwestern Hospital: A Retrospective Cohort Study

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S822-S823
Author(s):  
Rebecca Nirmal Kumar ◽  
Teresa Zembower ◽  
Valentina Stosor
Keyword(s):  
Cohort Study ◽  
Urinary Tract ◽  
Renal Transplant ◽  
Urinary Tract Infections ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Multidrug Resistant ◽  
Renal Transplant Recipients ◽  
Care Hospital ◽  
Tract Infections

Abstract Background Renal Transplant Recipients (RTR) are at high risk for Urinary Tract Infections (UTIs). However, the best empiric option for treatment is not well defined, because the prevalence of extended spectrum beta-lactamase (ESBL) Enterobacteriaceae and carbapenem resistant Enterobacteriaceae (CRE). The primary purpose of this study was to describe the prevalence of multidrug resistant UTIs in a contemporary cohort of RTR at a large Midwestern tertiary care hospital. Secondary outcomes evaluated frequency of key symptoms and physical exam findings, as well as characteristics of patients who developed multidrug resistant organisms, morbidity, and mortality. Methods This was a single-center retrospective cohort study. Patients were included if they were 18 years or older and underwent their transplant between July 11, 2019 and November 26, 2018. Statistical analysis was performed using Fischer’s Exact T-test for comparison of the patients with and without ESBL UTIs. Significance was defined by a p< 0.05 Results Two hundred fifty-two patients were evaluated (median age 54.4, 38.3% female gender), 36 patients developed UTIs, and no patients had CRE organisms. ESBL UTI prevalence was 7/252 (2.8%) among the total RTR population and 7/36 (19.4%) among the population of RTR who developed UTIs. Mortality rates did not differ significantly between patients with and without ESBL UTI (0% and 6.9%, respectively, p=.489) (Table 1). Additional clinical characteristics of the patients that developed ESBL UTIs were also obtained (Table 2). Table 1: Comparison of non-ESBL UTI and ESBL UTI Table 2: Characteristics of Patients with ESBL UTI Conclusion Prevalence of ESBL UTIs among RTR are low at a tertiary Midwestern hospital. Disclosures All Authors: No reported disclosures

Sign in / Sign up

Export Citation Format

Share Document